Alnylam enters $500M revolving credit facility maturing 2030

ALNYLAM PHARMACEUTICALS, INC.

• New $500M Revolving Credit Facility includes $150M letter of credit sublimit; available for working capital and general corporate purposes.
• Interest rates: Term SOFR plus 1.50%–2.50% (based on Total Leverage Ratio); commitment fee 0.20%–0.35% on unused commitments.
• Financial covenants: Total Net Leverage Ratio ≤ 3.75:1.00 and Consolidated Interest Coverage Ratio ≥ 3.00:1.00, tested quarterly.
• Maturity September 30, 2030; springing maturity if outstanding Springing Maturity Debt exceeds $630M or 100% of EBITDA.
• Guaranteed by material domestic subsidiaries and secured by substantially all assets, subject to customary exceptions and release conditions.